TerrAscend (TSNDF) Other Non-Current Liabilities (2020 - 2026)
TerrAscend's (TSNDF) quarterly Other Non-Current Liabilities came in at $1.7 million in Q1 2026, up 289.91% year-on-year from $446000.0 in Q1 2025, and down 45.45% on a QoQ basis from $3.2 million in Q4 2025.
TerrAscend (TSNDF) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.7 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 289.91% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 289.91% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 606.87% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.7 million, down from $3.2 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for TSNDF reached as high as $15.8 million in Q1 2023 and fell as low as $86000.0 in Q3 2025.
- Historically, Other Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $2.1 million in 2024.
- Across the five-year window, Other Non-Current Liabilities soared 1065.83% in 2023 and slumped 95.02% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $711000.0 in 2022, then soared by 626.02% to $5.2 million in 2023, then plunged by 91.26% to $451000.0 in 2024, then soared by 606.87% to $3.2 million in 2025, then slumped by 45.45% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.7 million in Q1 2026, $3.2 million in Q4 2025, and $86000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 178,000.00 |
| Mar 31, 2025 | 446,000.00 |
| Dec 31, 2024 | 451,000.00 |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 6.08 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | 15.84 Mn |
| Dec 31, 2022 | 711,000.00 |
| Sep 30, 2022 | 679,000.00 |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Dec 31, 2020 | 132.26 Mn |